1: Hoy SM. Contezolid: First Approval. Drugs. 2021 Sep;81(13):1587-1591. doi: 10.1007/s40265-021-01576-0. Erratum in: Drugs. 2021 Nov;81(16):1945. PMID: 34365606; PMCID: PMC8536612.
2: Kaul G, Dasgupta A, Chopra S. Contezolid in complicated skin and soft tissue infection. Drugs Today (Barc). 2022 Jul;58(7):315-326. doi: 10.1358/dot.2022.58.7.3389002. PMID: 35851867.
3: Hoy SM. Correction to: Contezolid: First Approval. Drugs. 2021 Nov;81(16):1945. doi: 10.1007/s40265-021-01627-6. Erratum for: Drugs. 2021 Sep;81(13):1587-1591. PMID: 34687423; PMCID: PMC9172673.
4: Yuan H, Wu H, Zhang Y, Huang H, Li Y, Wu J, Cao G, Yu J, Guo B, Wu J, Yuan Z, Chen Y, Yang W, Wu X, Zhang J. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0243021. doi: 10.1128/aac.02430-21. Epub 2022 May 16. PMID: 35575579; PMCID: PMC9217102.
5: Guo Q, Xu L, Tan F, Zhang Y, Fan J, Wang X, Zhang Z, Li B, Chu H. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0088921. doi: 10.1128/AAC.00889-21. Epub 2021 Aug 30. PMID: 34460305; PMCID: PMC8522767.
6: Yang M, Zhan S, Fu L, Wang Y, Zhang P, Deng G. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12. PMID: 35418550.
7: Li B, Liu Y, Luo J, Cai Y, Chen M, Wang T. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment. Front Pharmacol. 2023 Apr 24;14:1157437. doi: 10.3389/fphar.2023.1157437. PMID: 37168994; PMCID: PMC10165100.
8: Wu X, Meng J, Yuan H, Zhong D, Yu J, Cao G, Liu X, Guo B, Chen Y, Li Y, Shi Y, Gordeev MF, Wu J, Zhang J. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0040921. doi: 10.1128/AAC.00409-21. Epub 2021 Aug 16. PMID: 34398672; PMCID: PMC8522743.
9: Wang S, Cai C, Shen Y, Sun C, Shi Q, Wu N, Zheng S, Qian J, Zhang R, Zhou H. In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China. Front Microbiol. 2021 Aug 19;12:729900. doi: 10.3389/fmicb.2021.729900. PMID: 34489919; PMCID: PMC8417360.
10: Pi R, Chen X, Meng J, Liu Q, Chen Y, Bei C, Wang C, Gao Q. Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0103422. doi: 10.1128/aac.01034-22. Epub 2022 Oct 3. PMID: 36190243; PMCID: PMC9578412.
11: Wang W, Voss KM, Liu J, Gordeev MF. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29. PMID: 33913699.
12: Guo W, Hu M, Xu N, Shangguan Y, Xia J, Hu W, Li X, Zhao Q, Xu K. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents. 2023 Aug;62(2):106875. doi: 10.1016/j.ijantimicag.2023.106875. Epub 2023 Jun 3. PMID: 37276894.
13: Wu J, Cao G, Wu H, Chen Y, Guo B, Wu X, Yu J, Ni K, Qian J, Wang L, Wu J, Wang Y, Yuan H, Zhang J, Xi Y. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive- Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother. 2020 May 21;64(6):e02158-19. doi: 10.1128/AAC.02158-19. PMID: 32229495; PMCID: PMC7269508.
14: Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S, Xu Y, Wang H, Dai Q, Liu C, Wang X, Yuan Z, Gordeev MF. Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies. ACS Med Chem Lett. 2022 Jun 29;13(7):1030-1035. doi: 10.1021/acsmedchemlett.2c00191. PMID: 35859881; PMCID: PMC9290071.
15: Wu J, Yang X, Wu J, Wang J, Wu H, Wang Y, Yuan H, Yang H, Wang H, Zhang J. Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis. Front Pharmacol. 2023 Mar 13;14:1135007. doi: 10.3389/fphar.2023.1135007. PMID: 36992830; PMCID: PMC10040594.
16: Wang XK, Yu J, Xie CY, Hu XX, Nie TY, Li X, Wang PH, Li GQ, Yuan H, Yang XY, Li CR, You XF. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration. J Antimicrob Chemother. 2023 Jul 5;78(7):1632-1636. doi: 10.1093/jac/dkad138. PMID: 37202829.
17: Rodgers MP, Wertheim HFL. Comment on: A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022 Oct 28;77(11):3209-3210. doi: 10.1093/jac/dkac222. PMID: 35791752.
18: Zhao S, Zhang W, Zhang L, Zhang J, Li J, Si L, Ding Y, Li M, Song Y. Use of Contezolid for the Treatment of Refractory Infective Endocarditis in a Patient with Chronic Renal Failure: Case Report. Infect Drug Resist. 2023 Jun 13;16:3761-3765. doi: 10.2147/IDR.S413452. PMID: 37333679; PMCID: PMC10276592.
19: Wang Y, Wu H, Wu J, Fan Y, Liu X, Li Y, Hu J, Zhang J, Guo B. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Feb 15;1191:123129. doi: 10.1016/j.jchromb.2022.123129. Epub 2022 Jan 15. PMID: 35066246.
20: Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022 May 29;77(6):1762-1769. doi: 10.1093/jac/dkac073. PMID: 35265985.
